No Increase Seen in OD Deaths Involving Buprenorphine During COVID-19
Proportion of overdose deaths did not increase in association with actions taken to ease access to buprenorphine
Diagnosis & Disease Information
Intranasal Nalmefene Gets Priority Review for Opioid Overdose Treatment
OPNT003 is an intranasal formulation containing the high affinity opioid antagonist, nalmefene.
Pediatric Cannabis Poisoning Increased With Edible Cannabis Sales
Canadian provinces permitting edible cannabis sales experienced much larger increases in hospitalizations for unintentional poisoning
December 2022 Recap: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in December 2022 for investigational products in development.
RiVive Nasal Spray Gets Priority Review for OTC Treatment of Opioid Overdose
RiVive is an opioid antagonist that reverses the effects of opioids, including respiratory depression, sedation, and hypotension.
Narcan Nasal Spray Gets Priority Review for OTC Treatment of Opioid Overdose
If approved, the OTC nasal spray would deliver 4mg of naloxone per spray.
Drug Overdose Death Rates Increased in Seniors From 2000 to 2020
For men aged 65 to 74 and 75 years or older, drug overdose death rates were higher for non-Hispanic Black men
Benzodiazepines Tied to Drug Overdose in Young People With Sleep Disorders
Findings even stronger for young people with a recent opioid prescription
FDA Moves Toward Making Overdose Antidote an Over-the-Counter Drug
If the overdose antidote drug naloxone becomes easier to obtain, it could save lives and help combat the U.S. opioid crisis
Xylazine-Containing Products Complicate Overdose Management, Warns FDA
Xylazine is centrally-acting alpha2-adrengeric agonist that was originally approved in 1972 as a sedative and analgesic for use in veterinary medicine.
